Mario Nardi

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer

Maria E.L. van der Burg, M. van Lent, Marc Buyse et al. · Obstetrical & Gynecological Survey · 1995 · 580 citations

Medicine, Oncology, Surgery +11

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

Sandro Pignata, Sabino De Placido, R. Biamonte et al. · BMC Cancer · 2006 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Comparison of short- and medium-term results between laparoscopically assisted and totally laparoscopic right hemicolectomy: a case-control study

Massimiliano Fabozzi, Rosaldo Allieta, Riccardo Brachet Contul et al. · Surgical Endoscopy · 2010 · 104 citations

Medicine, Surgery, General Surgery +6

Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer

R. Maisano, D. Azzarello, Maurizio Maisano et al. · Journal of Chemotherapy · 2012 · 51 citations

Medicine, Oncology, Pathology +17